Intensity Therapeutics, Inc. Common stock Total Liabilities
Intensity Therapeutics, Inc. Common stock total liabilities. Based on the latest financial reports, Intensity Therapeutics, Inc. Common stock (INTS) has total liabilities worth $2.31 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check INTS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Intensity Therapeutics, Inc. Common stock (2019–2025)
Total liabilities of Intensity Therapeutics, Inc. Common stock from 2019 to 2025. This chart illustrates how Intensity Therapeutics, Inc. Common stock's total liabilities have evolved over time, based on quarterly financial data.
Intensity Therapeutics, Inc. Common stock Competitors by Total Liabilities
The table below lists competitors of Intensity Therapeutics, Inc. Common stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
U-BX Technology Ltd.
NASDAQ:UBXG
|
USA | $1.37 Million |
|
Plascar Participações Industriais S.A
SA:PLAS3
|
Brazil | R$1.38 Billion |
|
Royal Hali Iplik Tekstil Mobilya Sanayi ve Ticaret AS
IS:ROYAL
|
Turkey | TL530.86 Million |
|
Presurance Holdings, Inc.
NASDAQ:PRHI
|
USA | $259.69 Million |
|
Platina Resources Ltd
AU:PGM
|
Australia | AU$391.93K |
|
Peppermint Innovation Ltd
AU:PIL
|
Australia | AU$2.65 Million |
|
Real Heart
ST:HEART
|
Sweden | Skr13.59 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Intensity Therapeutics, Inc. Common stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Intensity Therapeutics, Inc. Common stoc.
Liquidity & Leverage Metrics
Intensity Therapeutics, Inc. Common stock Total Liabilities Ratios Explained
Intensity Therapeutics, Inc. Common stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intensity Therapeutics, Inc. Common stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intensity Therapeutics, Inc. Common stock (2019–2025)
The table below shows the annual total liabilities of Intensity Therapeutics, Inc. Common stock from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.23 Million | +19.30% |
| 2024-12-31 | $1.86 Million | -54.88% |
| 2023-12-31 | $4.13 Million | -75.48% |
| 2022-12-31 | $16.86 Million | +21.26% |
| 2021-12-31 | $13.90 Million | +18.72% |
| 2020-12-31 | $11.71 Million | +795.60% |
| 2019-12-31 | $1.31 Million | -- |
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is… Read more